New combo immunotherapy tackles tough ovarian cancer
NCT ID NCT03026062
First seen Sep 30, 2025 · Last updated May 14, 2026 · Updated 35 times
Summary
This study tested two immunotherapy drugs, durvalumab and tremelimumab, in 100 people with ovarian, fallopian tube, or peritoneal cancer that came back or stopped responding to platinum-based chemo. The goal was to see if giving the drugs together or one after the other works better at controlling the cancer. The trial is now complete, and results help guide future treatment approaches for this hard-to-treat cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.